SYBX (Synlogic Corp) צמיחת רווחים בשנה הנוכחית

The GURU.Markets terminal provides the YoY earnings per share growth rate, with the current level sitting around 0.00. Synlogic, Inc. (SYBX) develops synthetic bacteria to combat metabolic disruptions in the gastrointestinal tract. However, a freeze in development and a shortage of funds create a bankruptcy risk. The company is currently liquidating assets and restructuring, incurring heavy expenses to settle its obligations.

For Synlogic, Inc., as an innovator in the field of synthetic biotics, this metric reflects the efficiency of monetizing R&D resources. The annual earnings per share growth rate is calculated through a continuous comparison of the current EPS with the corresponding value from the previous period. Positive dynamics confirm the ability of the biotechnological potential to generate real cash flow. However, sharp spikes may indicate one-time operations rather than systemic success. Investors should assess the sustainability of the trend to forecast the long-term value of the asset.